Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate whether and to what extent the reported potent P-gp inhibitor clarithromycin
affects pharmacokinetic parameters (area under the curve (AUC) and maximal concentration
(Cmax)) of dabigatran.